SINGAPORE, Jan. 13, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage...
11-month sustained complete resolution of lung metastasis observed in Bria-OTS Phase 1/2a metastatic breast cancer study.No treatment limiting toxicities reported.Patient...
Received $35.8 million in gross proceeds from Series B warrant exercises, including full exercise by Coastlands Capital, Frazier Life Sciences...
- CX-2051 (varsetatug masetecan) Phase 1 Colorectal Cancer expansion data on track for Q1 2026 - - Varsetatug masetecan (“Varseta-M”)...
Potential to Be the First Targeted Fast-Acting Therapy for GBS, Setting a New Standard of Care BLA Submission with U.S./European...
Vancouver, British Columbia--(Newsfile Corp. - January 8, 2026) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB0) (OTCQB: BVAXF) ("BioVaxys" or...
Innovative Platform Aims to Boost Response Rates and Improve Lives of Cancer PatientsMADISON, Wis., Jan. 6, 2026 /PRNewswire/ -- Elephas...
FORT WORTH, Texas, Jan. 6, 2026 /PRNewswire/ -- NanOlogy, LLC, a clinical-stage oncology company, today announced the appointment of John...
~ Annual/Special Meeting of Shareholders to be Held on January 30, 2026 ~WEXFORD, Pa., Jan. 06, 2026 (GLOBE NEWSWIRE) --...
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, confirms...
-- Interim data from 14 patients with progressive lung cancers in dose-escalation cohorts of systemically administered Olvi-Vec-primed immunochemotherapy across ongoing...
WESTLAKE VILLAGE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced...
Board-certified providers share guidance on identifying allergy triggers and selecting treatments that align with each patient's symptoms and lifestyle. PHILADELPHIA,...
LAWRENCEVILLE, N.J., Dec. 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with...
- EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the first-line...
Tiziana reports excellent safety profile with intranasal foralumab after 37.4 patient-years cumulative exposureFDA denial of Sanofi’s tolebrutinib for nrSPMS shows...
NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage...
STAFFORD, Texas, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused...
--Plans to double the Number of Patients in Study-- --Company Expects Initial Findings to be presented in 2026-- BOCA RATON, Fla.,...
Year-End Recap Highlights Breakthrough Discoveries, Platform Advancements, and Strengthened Scientific LeadershipLehi, Utah, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Lehi, Utah,...